Eton Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

ETON$64.35+14.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations

(In thousands, except per share amounts)

	For the three months ended		For the nine months ended
	September 30,2026	September 30,2025	September 30,2026	September 30,2025
Revenues:
Product sales, net	$57,925	$22,459	$119,780	$55,383
Licensing revenue	—	—	—	3,286
Total net revenues	57,925	22,459	119,780	58,669
Cost of sales:
Product sales and royalties, net	13,624	14,604	35,331	28,204
Licensing revenue	—	—	—	825
Total cost of sales	13,624	14,604	35,331	29,029
Gross profit	44,301	7,855	84,449	29,640
Operating expenses:
Research and development	5,271	1,112	8,139	5,985
General and administrative	16,017	8,106	38,089	26,963
Total operating expenses	21,288	9,218	46,228	32,948
Income (loss) from operations	23,013	(1,363)	38,221	(3,308)
Other expense:
Interest and other expense, net	(656)	(592)	(2,572)	(2,664)
Income (loss) before income tax (benefit) expense	22,357	(1,955)	35,649	(5,972)
Income tax (benefit) expense	(12,892)	(28)	(12,732)	112
Net income (loss)	$35,249	$(1,927)	$48,381	$(6,084)
Net income (loss) per share, basic	$1.23	$(0.07)	$1.74	$(0.23)
Weighted average number of common shares outstanding, basic	28,661	26,893	27,855	26,891
Net income (loss) per share, diluted	$1.06	$(0.07)	$1.48	$(0.23)
Weighted average number of common shares outstanding, diluted	33,264	26,893	32,740	26,891

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.